A three-marker panel of Ca19–9, CEACAM-1, and MIA differentiated patients with pancreatic cancer from benign pancreatic conditions such as CP, with an AUC of 0.86. This evidence concerns the gene CEACAM1 and familial pancreatic carcinoma.